Testing effectiveness (Phase 2)UnknownNCT06345300
What this trial is testing
NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study
Who this might be right for
Borderline Resectable Pancreatic Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 40